CAPTRUST Financial Advisors
AKBA icon

CAPTRUST Financial Advisors’s Akebia Therapeutics AKBA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.6K Buy
+54,006
New +$64.3K ﹤0.01% 3111
2025
Q4 		– Sell
-10,042
Closed -$27.4K – 2740
2025
Q3 		$27.4K Buy
+10,042
New +$33.4K ﹤0.01% 2593
2025
Q2 		– Sell
-32,663
Closed -$62.7K – 2510
2025
Q1 		$62.7K Buy
32,663
+19,952
+157% +$40.7K ﹤0.01% 2270
2024
Q4 		$24.2K Buy
+12,711
New +$22.1K ﹤0.01% 2269
2022
Q2 		– Sell
-10
Closed – – 4918
2022
Q1 		$0 Hold
10
– – ﹤0.01% 4901
2021
Q4 		$0 Hold
10
– – ﹤0.01% 4753
2021
Q3 		$0 Sell
10
-357
-97% -$1.02K ﹤0.01% 4622
2021
Q2 		$1K Sell
367
-95
-21% -$320 ﹤0.01% 4295
2021
Q1 		$2K Buy
+462
New +$1.66K ﹤0.01% 4003

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

CAPTRUST Financial Advisors's AKBA Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 54,006 shares worth $61.6K. The stake represents ﹤0.01% of the portfolio and ranks #3111 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in AKBA as recently as Q3 2025.

CAPTRUST Financial Advisors first reported a position in AKBA in Q1 2021 and has held it in 9 quarters since. The position peaked at $62.7K in Q1 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • CAPTRUST Financial Advisors held 54,006 shares of Akebia Therapeutics worth $61.6K as of Q2 2026.
  • Akebia Therapeutics was a new CAPTRUST Financial Advisors position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3111 holding.
  • CAPTRUST Financial Advisors first reported a position in Akebia Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • CAPTRUST Financial Advisors's Akebia Therapeutics position peaked at $62.7K in Q1 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.